Bain Capital Life Sciences — 2020 Investments
3 investments dated 2020 · listed companies and verified rows first · show all
Solid Biosciences is a precision genetic medicine company developing a pipeline of gene therapy candidates for rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy, Friedreich's ataxia, CPVT, and TNNT2-mediated dilated cardiomyopathy.
BiotechHealthtechCharlestown, US
Stephen DiPalma(Executive Officer)Alexander (Bo) Cumbo(Executive Officer, Director)Carl Morris(Executive Officer)Martin Freed(Director)Paul Herizch(Executive Officer)Robert Huffines(Director)
Board seatAdam M. Koppel· per SEC Form D
Co-investorsForesite CapitalRA Capital
JenaValve manufactures the Trilogy Transcatheter Heart Valve System, an FDA-approved device for treating severe aortic regurgitation in high-risk patients who cannot undergo surgical valve replacement.
HealthtechMedical DevicesIrvine, US
Victoria Carr-Brendel(Executive Officer, Director)Hans-Reiner Figulla(Director)David Drachman(Executive Officer, Director)
BoardArnd Kaltofen(Director)inErik Amble(Director)Peter Barrett(Director)
Board seatAndrew Hack· per SEC Form D
Co-investorsAndera PartnersVI Partners
CereVasc is developing the eShunt System, a minimally invasive device intended to treat communicating hydrocephalus in children and adults as an alternative to invasive neurosurgical procedures.
BiotechHealthtechMedical DevicesAuburndale, US
Carl Heilman(Director)Daniel Levangie(Executive Officer, Director)Leslie Teso-Lichtman(Executive Officer)Frederick Callori(Director)Patrick Sullivan(Director)Aaron Levangie(Executive Officer)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.